|
|
Omniab Inc
OABI's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Omniab Inc 's sales fell
by -23.83 % in III. Quarter 2024 from the same quarter a year ago.
Medical Laboratories industry recorded
growth of revenues by 6.57 %
Omniab Inc net loss increased from $-16 millions, to $-16 millions in III. Quarter 2024,
• More on OABI's Growth
|
|
Omniab Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 64.6 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
-0 |
|
PE TTM
|
|
Company's Price to Sales ratio is at 18.96.
Medical Laboratories industry's Price to Sales ratio is at 3.05.
• More on OABI's Valuation
|
|
|
|
|
Omniab Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 64.6 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
-0 |
|
PE TTM
|
|
Company's Price to Sales ratio is at 18.96.
Medical Laboratories industry's Price to Sales ratio is at 3.05.
Omniab Inc Price to Book Ratio is at 1.33 lower than Industry Avg. of 381.46. and higher than S&P 500 Avg. of 0.01
• More on OABI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
